Cao et al. investigated the therapeutic potential of neutralizing antibodies targeting VEGF-B (with anti-VEGF-B antibody) and IL-17A (with anti-IL-17A antibody) in a mouse model of DKD. Here, VEGFB is linked to diabetic kidney disease.